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Abstract
Toxoplasmosis, caused by the protozoan Toxoplasma gondii, is a worldwide disease
whose clinical manifestations include encephalitis and congenital malformations in new-
borns. Previously, we described the synthesis of new ethyl-ester derivatives of the antibiotic
ciprofloxacin with ~40-fold increased activity against T. gondii in vitro, compared with the
original compound. Cipro derivatives are expected to target the parasite’s DNA gyrase com-
plex in the apicoplast. The activity of these compounds in vivo, as well as their mode of ac-
tion, remained thus far uncharacterized. Here, we examined the activity of the Cipro
derivatives in vivo, in a model of acute murine toxoplasmosis. In addition, we investigated
the cellular effects T. gondii tachyzoites in vitro, by immunofluorescence and transmission
electron microscopy (TEM). When compared with Cipro treatment, 7-day treatments with
Cipro derivatives increased mouse survival significantly, with 13–25% of mice surviving for
up to 60 days post-infection (vs. complete lethality 10 days post-infection, with Cipro treat-
ment). Light microscopy examination early (6 and 24h) post-infection revealed that 6-h
treatments with Cipro derivatives inhibited the initial event of parasite cell division inside
host cells, in an irreversible manner. By TEM and immunofluorescence, the main cellular ef-
fects observed after treatment with Cipro derivatives and Cipro were cell scission inhibition -
with the appearance of ‘tethered’ parasites –malformation of the inner membrane complex,
and apicoplast enlargement and missegregation. Interestingly, tethered daughter cells re-
sulting from Cipro derivatives, and also Cipro, treatment did not show MORN1 cap or
centrocone localization. The biological activity of Cipro derivatives against C. parvum, an
apicomplexan species that lacks the apicoplast, is, approximately, 50 fold lower than that in
T. gondii tachyzoites, supporting that these compounds targets the apicoplast. Our results
show that Cipro derivatives improved the survival of mice acutely infected with T. gondii and
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inhibited parasite replication early in the first cycle of infection in vitro, highlighting their ther-
apeutic potential for the treatment of toxoplasmosis.
Introduction
Toxoplasma gondii, the causative agent of toxoplasmosis, is a globally spread parasite infecting
approximately one third of the human population. Toxoplasmosis has a broad spectrum of
clinical presentations. Infection of the central nervous system by this parasite is associated to
encephalitis and eye disease. Indeed, the vertical transmission during pregnancy can lead to
abortion and congenital malformations in the newborn [1].Whereas infections by this parasite
are usually asymptomatic in most individuals, T. gondii is an important opportunistic pathogen
with high mortality and morbidity in immunocompromised patients [2]. Indeed, ocular toxo-
plasmosis rates can be extremely high, even in immunocompetent individuals, especially in
South American countries [2–4].
Despite the worldwide prevalence of this potentially serious medical condition, toxoplasmo-
sis treatment is limited to a small number of drugs that are associated with numerous side ef-
fects. The combination of pyrimethamine with sulfadiazine is the first choice of treatment for
toxoplasmosis; however, patients often do not tolerate sulfadiazine, and long-term treatment
(4–6 weeks) with this drug is commonly associated with gastrointestinal disorders that lead to
treatment discontinuation. In patients with intolerance to sulfadiazine, pyrimethamine is com-
bined with clindamycin or atovaquone, which also cause gastrointestinal disorders [5,6]. Over-
all, it is clear that the development of alternative or replacement treatments for toxoplasmosis
is vital for improving disease treatment and control.
The discovery of a ‘relic’ chloroplast (apicoplast) in apicomplexan parasites – a group that
includes T. gondii and also Plasmodium spp., the causative agents of malaria—brought new
possibilities for the identification of novel targets for therapy against these parasites [7, 8]. Al-
though photosynthetic function was lost during apicoplast evolution, this organelle still har-
bors many metabolic pathways of prokaryotic origin and whose functions are essential for
parasite survival [9, 10]. Due to their prokaryotic origins, the apicoplast pathways represent in-
teresting targets for the development of specific anti-parasitic compounds with limited toxicity
to host cell pathways of eukaryotic origin. The chemotherapeutic potential of the metabolic ac-
tivities operating in the apicoplast is well recognized [8, 11–13], the antibiotics clindamycin
and azithromycin, inhibitors of apicoplast protein synthesis, are already in clinical use as a sec-
ond-line therapy for toxoplasmosis treatment [5].
Among apicoplast pathways, DNA replication is an important potential chemotherapeutic
target. Fluoroquinolones are known DNA replication inhibitors that target prokaryotic type II
topoisomerases (DNA gyrase and topoisomerase IV) [14] These antibiotics have a broad spec-
trum of activity against various pathogens, including bacteria, mycoplasma, and protozoan
parasites [15, 16]. They are generally well tolerated by most patients, and are commonly used
in the clinic [17].
DNA gyrases introduce negative supercoiling into the DNA strand during DNA replication
and transcription. The DNA gyrase enzymatic complex is formed of two copies of both A and
B subunits (A2B2); subunits A catalyze DNA double-strand breaks, while subunits B have
ATPase function [14]. Homologues of DNA gyrase subunits A and B genes are found in the
nuclear genome of apicomplexan parasites (probably as a result of gene transfer from the or-
ganelle’s ancestral genome, during apicoplast evolution), and their protein products are
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targeted exclusively to the apicoplast [18]. Pharmacological inhibition of subunits A and B of
the apicoplast’s DNA gyrase – by fluoroquinolone and novobiocin, respectively—inhibit apico-
plast genome replication and affect parasite viability, validating this enzyme as a potential drug
target in apicomplexans [8, 19].
In a previous work, we described the synthesis and in vitro tests against P. falciparum and T.
gondii of novel ester prodrugs of ciprofloxacin (Cipro), a known fluorquinolone [20]. Chemical
modifications of the reference compound yielded, on average, a 40-fold increase in the anti-
parasitic activity compared with the original molecule, and Cipro derivatives had low toxicity
against mammalian cells (murine splenocytes and the LLCMK2 epithelial cell line) [20].
Among the ester prodrugs of Cipro tested against T. gondii in vitro, compounds 2 (pro-
drug), 4 (phenyl substituent) and 5 (adamantanyl substituent) were particularly potent, with
IC50 values in the nanomolar or low micromolar range (0.42 μM and 0.46 μM, for compounds
2 and 5, respectively, and 1.24 μM for compound 4, after 48 h of treatment) [20]. The presence
of ethyl esters on the carboxyl of Cipro contributed to increase the activity of these derivatives
compared with that of the original compound [20]. Esterification of Cipro into prodrug com-
pounds is expected to make the original molecule more lipophilic, favoring the diffusion across
biological membranes—including the multiple membranes of T. gondii, and also those of the
apicoplast, which harbors the likely target of Cipro derivatives (DNA gyrase).
Although the Cipro derivatives synthesized and described by us previously are expected to
target the apicoplast’s DNA gyrase complex, their cellular mode of action in apicomplexans
has not been examined. Also, these drugs were not tested in vivo against infections by
apicomplexan parasites.
In the present study, we evaluated the activities of compounds 2, 4 and 5 against T. gondii
infection in vivo, in a murine model of acute toxoplasmosis. Also, we characterized the cellular
effects of these compounds – henceforth referred to as Et-Cipro (compound 2), Ph-Cipro
(compound 4), and Adam-Cipro (compound 5)—to elucidate their mode of action in T. gondii.
We show that Et-cipro and Adam-cipro treatment increased mouse survival compared with
Cipro treatment, disrupted parasite cell division and affected apicoplast segregation. Interest-
ingly, Cipro derivatives could not inhibit the proliferation of Cryptosporidium parvum, an api-
complexan species that lacks the apicoplast.
Materials and Methods
Ethical Statement
The experimental protocols for animal use in this study were approved by the institutional Eth-
ics Committee for Animal Use (CEUA, IBCCF, UFRJ: approval IDs 208-09/16 and 206-09/16;
CEUA Fiocruz—LW-16/13), and are in agreement with the Brazilian federal law (11.794/2008,
Decreto n° 6.899/2009).
Parasites and Mice
In this study, we used tachyzoite forms the RH strain of Toxoplasma gondii, obtained from the
peritoneal cavity of mice 2 days after infection [21]. Four to six-week-old female Swiss mice
(18–22 g) were used for the in vivo experiments. Drinking water and food were given ad
libitum.
In vivo toxicity analysis
Acute toxicity analysis was performed using non-infected female Swiss mice (19–21 g). Mice
were administrated a single oral dose of Et-Cipro, Ph-Cipro or Adam-Cipro (25, 50, 100, or
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200 mg/kg/day) and monitored for a period of 48 hours for the appearance of toxic and sub-
toxic symptoms (weight body loss and animal behavior alterations). During the toxicity analy-
sis no animal has died, then after the 48h period of observation after drug administration mice
were anesthetized with CO2 and blood was collected by cardiac puncture to determine the
serum levels of urea and creatinine kinase at CECAL/Fiocruz platform (Ortho Clinical-John-
son & Johnson), as reported previously [22].
To determine compound efficacy against T. gondii in vivo, female Swiss mice were infected
intraperitoneally (i.p.) with 5x103 T. gondii tachyzoites and treated with test compounds from
24 h post-infection. Groups of 3–4 mice were housed per cage and arbitrarily assigned to one
of the following treatment groups: Cipro, Et-Cipro, Ph-Cipro or Adam-Cipro (50–150 mg/kg/
day), or untreated (i.e., treated with vehicle, polyethylene glycol/PEG). Mice were treated once
daily for 7 days, by oral gavage, and mouse mortality was monitored once a day for a period of
60 days. During survival studies, mice were not inflicted to any suffering condition and mice
presenting morbidity symptoms (shivering, ruffled hair and immobility) were euthanized by
CO2 asphyxiation to minimize animal suffering, and then mortality was scored. Survival curves
were calculated using the Kaplan and Meier method, and compared using the log-rank (Man-
tel-Cox) test, in GraphPad Prism 5.0 (GraphPad Software Inc.) and P<0.05 was considered sta-
tistically significant. The following numbers of mice were used in this study: in untreated
groups, n = 10 (Cipro control) or n = 14/15 (Et-Cipro, Ph-Cipro and Adam-Cipro controls), in
3–4 groups; in Cipro groups, n = 11 (50 and 100 mg; 3 groups) and n = 8 (150 mg Cipro; 2
groups); in Et-Cipro groups, n = 11 (50 and 100 mg; 3 groups); in Ph-Cipro groups, n = 8 (50
and 100 mg; 2 groups) and n = 11 (150 mg; 3 groups); and in Adam-Cipro groups, n = 3
(50 mg; 1group) and n = 12 (100 mg; 3 groups).
Drug treatments in vitro
For the treatment of T. gondii tachyzoites with Cipro derivatives in vitro, 5x105 LLC-MK2 cells
(ATCC CCL7, Rockville, MD/EUA) in RPMI medium were plated on coverslips inside 24-well
tissue culture plates, and allowed to settle at 37°C (5% CO2) for ~24h. Then, cells were infected
with parasites (freshly-harvested from infected mice) at a 10:1 ratio of parasites to host cells.
Tachyzoites were allowed to interact with host cells for 1 h, cell monolayers were washed three
times with medium (to remove extracellular parasites) and then treated with different concen-
trations of Cipro (20–50μM), Et-Cipro (0.5–5 μM), or Adam-Cipro (0.5–5 μM), for 6 h at
37°C. Then, coverslips were fixed with Bouin and stained with panoptic (solutions 2 and 3 of
the ‘Panotico rápido’ kit, from Laborclin Ltda., Paraná, Brazil). Alternatively, cultures were
washed three times with 0.5 ml of medium (to remove test compounds) and incubated for an
additional 18 h in medium without drugs, before fixing and staining. The number of parasites
per vacuole was scored by direct light microscopy examination. Three independent experi-
ments were performed for each treatment condition, and the results were analyzed by two-way
ANOVA (using GraphPad Prism 5.0).
For plaque assay, 6-well tissue culture plates were seeded with human foreskin fibroblasts
(HFF; ATCC). HFF was grown in high glucose Dulbeco’s Modified Eagle Medium supple-
mented with 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin
and maintained at 37°C with 5% CO2. After cultures reached confluence each well was infected
with 104 of T. gondii. Infected cultures were treated for 10 days with Cipro derivatives, Cipro or
left untreated.
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Immunofluorescence microscopy
For immunofluorescence assays, LLC-MK2 cells infected with tachyzoites at a 10:1 ratio of par-
asites to host cells were treated with Et-Cipro, Adam-Cipro and Ph-Cipro compounds for 24 h.
For Cipro assay, cells were infected in a ratio of 5:1 parasites per host cell and treated for 24,
48 and 72h. After treatment, infected cells were fixed in 3.7% freshly-prepared formaldehyde,
permeabilized with 0.5% Triton X-100 for 15 min, and blocked with 3% bovine serum albumin
(BSA) in PBS at pH 7.4 and room temperature for 1 h. All antibody incubations were per-
formed in 3% BSA in PBS, for 1h, at room temperature. The following primary antibodies were
used: anti-SAG1 (kindly provided by Dr. John Boothroyd, Stanford University School of Medi-
cine, USA), at a dilution of 1:1000; anti-HSP60 and anti-Morn1 (kindly provided by Dr. Boris
Striepen, University of Georgia, USA), diluted to 1:2000 and 1:100, respectively; and anti-
IMC1 (kindly provided by Dr. Gary Ward, University of Vermont, USA), diluted to 1:1000.
The secondary antibodies used here were anti-mouse/rabbit coupled to Alexa 488 or 546 (Mo-
lecular Probes). Sytox green (Molecular Probes) and DAPI (Sigma-Aldrich) were used to label
the DNA. After labeling, the coverslips were mounted onto slides using Prolong gold (Life
Technologies), and samples were examined on a TCSSP5 Leica or Zeiss LSM710 laser scanning
confocal microscopes.
Transmission electron microscopy (TEM)
For TEM, LLC-MK2 cultures were infected with tachyzoites as described above and then treat-
ed with 1 and 5 μM Et-Cipro and Adam-Cipro for 24 and 48 h, 20 μMCipro for 48 and 72h
or left untreated (control). After treatment, cells were fixed in 2.5% glutaraldehyde in 0.1 M so-
dium cacodylate buffer (pH 7.4), and post-fixed for 45 min (and in the dark) in 1% osmium
tetroxide, 1.25% potassium ferrocyanide and 5 mM CaCl2, in 0.1 M sodium cacodylate buffer
(pH 7.4). Samples were dehydrated in acetone solutions of increasing concentrations (30–
100%) and embedded in PolyBed (Polyscience Inc., Warrington, PA, USA). Ultrathin sections
were stained with uranyl acetate and lead citrate, and then observed in a Zeiss 900 Electron Mi-
croscope (Carl Zeiss, Inc.) or in a Jeol 1200 EX electron microscope (Jeol LTD, Tokyo, Japan).
Cryptosporidium parvum in vitro assay
C. parvum oocysts obtained from infected neonatal calves (Institut National de la Recherche
Agronomique-INRA, Nouzilly, France) were purified as previously described [23] and stored
in PBS at 4°C. Madin Darby bovine kidney cell line (MDBK; ECACC # 88081201, Sophia Anti-
polis, France) was cultured at 37°C in a 5% CO2 moist atmosphere in growth medium: RPMI
1640 (Sigma, L’Isle d’Abeau, France) supplemented with 25 mMHEPES (Sigma H-3375), 200
U/ml of penicillin, 200 μg/ml of streptomycin (Sigma P-0781) and 10% fetal calf serum (FCS;
Dutscher, Brumath, France).
Prior to infection, MDBK cells were trypsinized and seeded in just one well of a 24-well
plate in 2 ml of RPMI 1640 with 1% FCS. Aseptic oocysts were prepared for excystation by in-
cubation in RPMI-1640, pH 2 (for 30 min at 37°C). Then, oocytes were washed in RPMI 1640
with 1% FCS and allowed to interact with MDBK cells for 1.5 h at 37°C in a 5% CO2 atmo-
sphere. After 3 washes by centrifugation at 160 g in RPMI 1640 to remove non-excysted oocysts
and shells, infected cells were plated in 24-well plates containing glass coverslips, in 500 μl/well
of RPMI/1%FCS, and allowed to settle for 24 h. The infected cells were subsequently washed 3
times with RPMI 1640 and allowed to grow for a further 5 h (in 500 μl/well of RPMI/1% FCS).
500 μl of medium containing twice-concentrated Cipro derivatives were then added in tripli-
cates in an equal volume of growth medium and left for another 24 h. Cells were fixed in 100%
methanol and stained with 20% Giemsa and 1% Alcian blue as previously described [24], and
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the effects against sporozoite proliferation were evaluated by examining at least 1000 cells/cov-
erslip in a light microscope, using an oil immersion X100 objective.
Results
Cipro derivatives increased the survival of mice acutely infected with T.
gondii
In a previous study, we showed that new prodrugs derivatives of the known antibiotic cipro-
floxacin were at least 40 fold more active than the original molecule against T. gondii tachy-
zoites, the form of the parasite that causes acute disease [20]. In preparation for in vivo testing
of ciprofloxacin derivatives against T. gondii infection in mice, we performed an acute toxicity
analysis of the test compounds using a ‘single-dose assay’, where uninfected mice were admin-
istered with a single oral dose of 25–200mg/kg of Cipro derivatives, and then monitored for
side effects for up to 48 h. During the toxicity assay, no animal has died and no alterations in
mouse behavior or body weight gain were observed 48 h after drug administration (Table 1).
Biochemical assays showed that serum urea levels increased 48 hours after treatment with
Cipro derivatives; however, this was also observed in vehicle-treated animals. Mice treated with
higher doses of Et-Cipro and Adam-Cipro showed normal serum levels of creatinine kinase,
but animals treated with 200 mg/kg of Ph-Cipro had slightly altered serum levels of
this enzyme.
Swiss mice were administrated with a single oral dose of different ciprofloxacin derivatives,
and monitored for 48h.
Table 1. Toxicity of ciprofloxacin derivatives in mice.
Compound dose (mg/kg) Mouse weight (g) Serum ureaa Serum creatinine kinaseb
Initial After 48 h
Vehicle 20.15 21.28 53.0 ND
Et-Cipro 25 19.87 22.25 55.8 1727
50 19.15 20.92 51.2 182
100 20.71 22.27 55.1 578
200 20.0 22.17 49.3 583
Vehicle 19.30 21.91 48.0 420
Adam-Cipro 25 20.65 23.10 ND ND
50 20.80 22.12 ND ND
100 20.45 23.50 ND ND
200 21.11 23.28 51.5 467
Vehicle 19.49 22.94 46.7 563
Ph-Cipro 25 21.21 23.85 49.2 ND
50 19.30 22.72 50.6 506
100 19.21 21.94 52.8 ND
200 19.93 22.20 46.2 1541
Swiss mice were administrated with a single oral dose of different ciprofloxacin derivatives, and monitored for 48h.
Serum levels of urea and creatinine kinase were measured in blood samples harvested 40h after drug administration. The following reference values
(mg/kg) were used:
a18–29 mg/dL
b,  1070 U/L.
doi:10.1371/journal.pone.0125705.t001
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Treatment of mice infected with T. gondii tachyzoites with non-toxic doses of Cipro deriva-
tives for 7 days resulted in increased mouse survival (Fig 1A–1D). All mice treated with Cipro
died by day 10 post-infection (Fig 1A). In contrast, significantly increased survival of T. gondii-
infected mice was observed after treatment with 50 mg/kg/day Et-Cipro (18%; P< 0.05; Fig
1B) or 100 or 150 mg/kg/day Ph-Cipro (13 and 18%, respectively; P<0.05; Fig 1C), or 100 mg/
kg/day Adam-Cipro (25%; P<0.05; Fig 1D). These mice were still alive 60 days post-infection
(Fig 1). Brain examination of 60-days survived mice did not show encysted parasites (presence
of chronic infection) (data not shown).
Cipro derivatives inhibit T. gondii cell division early during infection
Tachyzoites of the RH strain of T. gondii have a doubling time of around 6–8 h inside the para-
sitophorous vacuole of infected cells [25]. Treatment of infected cells with different concentra-
tions of Et-Cipro, Adam-Cipro, and Cipro for just 6 h (7 h total infection) significantly
decreased the number of parasitophorous vacuoles containing two parasites (as a result of cell
division after invasion) compared with untreated controls, showing that the Cipro derivatives
had an early effect on parasite division (Fig 2A). Adam-Cipro was the most active, as even low
concentrations of this derivative (0.5 μM and 1 μM) significantly inhibited parasite division
compared with untreated controls. The effect of treatment with 0.5 μM of Adam-Cipro was
similar to that of 50 μMCipro, with 70% and 68% of the parasitophorous vacuoles having just
one parasite, respectively, corresponding to an 100-fold increase in activity for Adam-Cipro
compared with the original compound. In contrast, higher concentrations of Et-Cipro
(>2 μM) were required to affect parasite division significantly (Fig 2A). Nevertheless, the effect
of 2 μM of Et-Cipro on early parasite division was similar to that of 20 μM of Cipro, with 57%
Fig 1. Effect of 7-day treatment with different doses of Cipro derivatives on the survival mice. SwissWebster mice were infected i.p. with 5x103
tachyzoites of T. gondii (RH strain) one day prior to the start of treatment. Results were evaluated by the Kaplan-Meier product limit method, and compared
using the log-rank (Mantel-Cox) test. * P<0.05 vs. untreated controls. The numbers of treated mice in each group were: untreated, 10 (A), 14 (B and D) and
15 (C); 50 and 100 mg Cipro, 11 (three groups each); 150 mg Cipro, 8 (two groups); 50 and 100 mg Et-Cipro, 11 (three groups); 50 and 100 mg Ph-Cipro, 8
(two groups); 150 mg Ph-Cipro, 11 (three groups); 50 mg Adam-Cipro, 3 (one group); 100 mg Adam-Cipro, 12 (three groups).
doi:10.1371/journal.pone.0125705.g001
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and 54% of the vacuoles containing just one parasite, respectively, which represents a 10-fold
increase in cell division inhibition compared with the original compound.
The effect of Cipro derivatives on parasite division was sustained even after these com-
pounds were removed from the culture medium and infection was allowed to proceed for an
additional 18 h (Fig 2B). The number of parasites per vacuole for all Adam-Cipro treatments
was significantly lower than that observed in control, untreated cells, with less than 1% of vacu-
oles containing16 parasites in cells treated with 0.5 μM of Adam-Cipro. After treatment with
2 or 5 μM of Adam-Cipro, approximately 99% of vacuoles contained up to eight parasites only.
The presence of large numbers of vacuoles containing just one parasite 18 h after drug removal
shows that some parasites were irreversibly affected by Cipro derivatives treatment.
Fig 2. Early effects of ciprofloxacin (Cipro) derivatives in tachyzoite cell division inside host cells. (A) Tachyzoites of T. gondii were treated with Cipro
derivatives for 6 h, from 1–7 h post-infection, and the number of parasites per vacuole was analyzed by light microscopy. (B) After 6 h, the medium containing
drugs was removed and replaced with fresh medium without drugs. Tachyzoites were allowed to proliferate for an additional 18 h, and the number of
parasites per vacuole was counted. * P<0.05, results were analyzed by two-way ANOVA statistical test.
doi:10.1371/journal.pone.0125705.g002
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The antiproliferative effect of Cipro derivatives and Cipro was also confirmed by plaque
assay (S1 Fig). No growth was observed after 10 days treatment with 5 μM of Adam-Cipro or
Et-Cipro, 10 μM of Ph-Cipro and 20 of Cipro. In contrast, untreated cultures presented many
plaques. A significant decrease in parasite proliferation was also observed after treatment with
0.5 μMAdam-Cipro and 10 μMCipro.
Treatment with ciprofloxacin derivatives prevents daughter cell budding
(but not mitosis) during tachyzoite cell division
During T. gondii cell division by ‘endodyogeny’, two daughter cells are assembled in the interi-
or of the mother cell after a single round of DNA replication, the daughter inner membrane
complex (IMC) provides ‘scaffolding’ for the newly formed and segregating daughter cell com-
ponents [26, 27]. At the end of cytokinesis, the mother cell’s original IMC disassembles, and
daughter cells ‘bud out’ incorporating the mother cell’s plasma membrane and leaving behind
a residual body [26, 27]. Apicomplexan mitosis is ‘closed’, with the nuclear envelope remaining
intact throughout the process, and being easily recognizable by its U shape [27].
To elucidate the impact of treatment with Cipro derivatives on the T. gondii cell division
process, we evaluated the effect of Cipro derivatives by immunofluorescence microscopy using
antibody markers that recognize key parasite structures (Figs 3 and 4). Untreated parasites la-
beled with an antibody that recognizes SAG1, a major tachyzoite surface protein, and with
Sytox-green (to label the DNA) showed a typical ‘rosette’ organization within host cells, with
groups of parasites clustered with their apical/anterior ends projecting outwards, while their
posterior ends clustered at the center of the rosette (untreated; Fig 3). In rosettes found in un-
treated cells, there was one nucleus per parasite, and some parasites were in the process of nu-
clear division, as evidenced by the presence of U-shaped nuclei (Fig 3, arrowheads in
untreated). Treatment with 5 μM Et-Cipro and Adam-Cipro for 24 h led to the formation of
large multinucleated parasites (Fig 3, arrows), with loss of the typical rosette structure.
Given that Cipro targets the apicoplast, we evaluated the effect of the new Cipro derivatives
on the replication and division of this organelle, by observing dividing parasites labeled with
the anti-HSP60 (Fig 4). To confirm that treatment with Cipro derivatives led to cell division ar-
rest, cells were also labeled with an antibody that recognizes the specific IMC component
IMC1 to improve visualization of daughter cell boundaries in dividing parasites (Fig 4). In
non-dividing T. gondii tachyzoites, the IMC is a system of flattened vesicles associated to fila-
mentous network found below the plasma membrane, and the combined structures of the plas-
ma membrane and the IMC form the cell’s tri-laminar ‘pellicle’. In dividing parasites the IMC
scaffolds the new daughter cells [27]. The IMC is interrupted at the micropore region, and at
apical and basal ends of the parasite only [28–30]. While untreated parasites were clearly indi-
vidualized and displayed only one small and round apicoplast per cell (Fig 4A), labeling with
the anti-IMC1 antibody confirmed that treatment with 1 and 5 μM Et-Cipro and Adam-Cipro
and 10 μM Ph-Cipro led to parasite cell division arrest, with the formation of ‘tethered’ daugh-
ter cells (Fig 4B–4E, arrowheads). Some enlarged parasites displayed IMC profiles indicative of
the initiation of a new round of cell duplication prior to the completion of cytokinesis (Fig 4B–
4E). Thus, the multiple tethered T. gondii cells resulted from successive rounds of cell duplica-
tion combined with cytokinesis arrest. The quantification of vacuoles presenting abnormal par-
asite division process showed that the division arrest by Cipro derivatives was a common effect
and dose dependent (Fig 4F). Treatment with 5 μM of Adam-Cipro caused a drastic effect on
tachyzoite division, leading to the arrest of endodyogeny in 55% of the parasitophorous vacu-
oles scored. Vacuoles containing large parasites with multiple daughter cells were also observed
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in parasites treated with Cipro derivatives for just 6 h and allowed to grow for additional 18 h
without drugs (S2 Fig)
Parasite basal end widening (Fig 4B and 4D, asterisk) and apicoplast missegregation events
(Fig 4D, large arrows) were also observed after treatment with Cipro derivatives. Additionally,
some parasites treated with 5 μM Et-Cipro or Adam-Cipro displayed abnormally enlarged
lobe-shaped apicoplasts (Fig 4B and 4D, arrows).
Apicoplast missegregation events were also observed by fluorescence microscopy in tachy-
zoites treated for just 6 h with 2 μM Et-Cipro and 1 μMAdam-Cipro (Fig 4G). In these cells,
Fig 3. Cipro derivatives did not affect parasite mitosis. Parasites were labeled with anti-SAG1 (red, labeling the parasite’s cell surface) and Sytox green
(to label the DNA). After 24 h of infection, untreated (control) parasites (top row) were typically arranged in ‘rosettes’, and displayed normal morphology, with
one nucleus per cell. Many parasites were in the process of cell division, as evidenced by the presence of U-shaped mitotic nuclei (arrowheads). In cells
treated with 5 μM of Et-Cipro (middle row) or Adam-Cipro (bottom row) for 24 h, tachyzoites were able to complete nuclear division, as evidenced by the
presence of individualized nuclei, but could not complete cytokinesis, which led to the formation of multinucleated cells (arrows), and loss of the typical
rosette organization. Images represent maximum projections of optical slices from confocal laser scanning microscopy.
doi:10.1371/journal.pone.0125705.g003
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the divided apicoplast is clearly being excluded or mispositioned from one of the budding
daughter cells (arrows).
The analysis of the basal IMC gap length showed that the effect of Cipro derivatives in the
parasite basal end was significant after 24 h of treatment (Fig 4H). The distribution variation of
the basal gap extent was higher in parasites treated with Et-Cipro, Adam-Cipro and Ph-Cipro
compared to untreated control (Fig 4F). Whereas control parasites had a basal IMC length
mean of 0.65 ± 0.11 μm, parasites treated with Et-Cipro, Adam-Cipro or Ph-Cipro presented a
higher basal IMC length mean: 0.76 ± 0.20 μm (1 μM Et-Cipro), 0.80 ± 0.26 (5 μM Et-Cipro),
0.75 ± 0.20 (1 μMAdam-Cipro), 0.83 ± 0.34 (5 μMAdam-Cipro) and 0.73 ± 0.24 (10 μM Ph-
Cipro).
Ultrastructural analysis shows that Cipro derivatives affect IMC
formation, parasite budding and apicoplast positioning
To improve our understanding of the effects of Cipro derivatives on parasite cells, the ultra-
structure of treated intracellular tachyzoites was examined by TEM.
In untreated control cells, observation of the parasitophorous vacuole by TEM revealed pro-
files of T. gondii tachyzoites undergoing a normal cell division process (Fig 5A). In untreated
parasite with mitotic nuclei, newly formed IMCs (arrows) appeared to act as scaffolds for the
assembling of daughter cell components, with daughter apicoplasts (insets) found in the appro-
priate positions for the correct segregation of one apicoplast to each daughter cell (Fig 5A).
TEM analyses of cells infected with T. gondii and treated with either 1μM Et-Cipro for 48 h
(Fig 5B) or 5 μMAdam-Cipro for 24 h (Fig 5C) confirmed that these treatments led to budding
arrest, with the formation of ‘tethered’ parasites. Vacuoles showing large parasites (arrows)
containing multiple daughter cells (arrowheads; Fig 5B) or parasites united by their basal ends
(arrow; Fig 2C) were frequently observed, suggesting incomplete cytokinesis. Treatment with
Cipro derivatives also affected the IMC structure, since parasites displaying wide regions of the
cell surface devoid of an underlying IMC envelope were observed after 24 h treatments with
5 μMAdam-Cipro (Fig 5C) or 5 μM Et-Cipro (arrowheads; Fig 5D–5E).
Alterations in apicoplast inheritance during parasite cell division were also evident upon
TEM analysis of infected cells treated with Cipro derivatives (Fig 5D and 5F). In non-dividing
tachyzoites and in forming daughter cells, the apicoplast is always found at the anterior region
of the cell (Fig 5A), which is easily recognizable by the presence of a characteristic set of cyto-
skeletal components and secretory organelles (rhoptries and micronemes). Surprisingly, in in-
fected cells treated with Cipro derivatives and observed by TEM, the apicoplast was often
found at the posterior region of the parasite (i.e., posterior to the nucleus; Fig 5D), which is sug-
gestive of apicoplast mispositioning during cell division and, consequently, of incorrect inheri-
tance of this organelle by the forming daughter cells. Apicoplast missegregation was also
Fig 4. Cipro derivatives affected parasite daughter cells scission process. Immunofluorescence microscopy of LLC-MK2 cells infected with tachyzoites
of T. gondii and treated for 24 h with Cipro derivatives. Parasites were labeled with anti-HSP60 (recognizing the apicoplast, in green) and anti-IMC1
(recognizing the inner membrane complex or IMC, in red) antibodies. (A) Untreated (control) parasites were typically organized in ‘rosettes’ and had
apicoplasts of normal shape and size. Tachyzoites treated with (B) 5 μMEt-Cipro, or (C) 1 or (D) 5 μMAdam-Cipro or (E) 10 μMPh-Cipro, for 24 h, showed
enlarged and abnormally-shaped apicoplasts (arrows), signs of cell division arrest (such as ‘tethered’ parasites, arrowheads), abnormally-shaped basal
complexes (asterisks), and also missegregated apicoplasts (thick arrows) that were left outside daughter cell boundaries (marked by the anti-IMC1 labelling).
Images represent optical slices (untreated) or maximum projections of optical slices (Et-Cipro and Adam-Cipro). (F) Quantification of vacuoles (n = 120)
containing parasites presenting cell division arrest after treatment with Cipro derivatives for 24h, results are the mean of two independent experiments. (G)
Apicoplast segregation (arrowhead) and parasite division defects were observed as a result of Cipro derivative treatment in the first event of tachyzoite
division inside host cells. (H) Comparison of the distribution of basal IMC gap length in untreated control (n = 143), 1 μMEt-Cipro (n = 149), 5 μMEt-Cipro
(n = 144), 1 μMAdam-Cipro (n = 150), 5 μMAdam-Cipro (n = 147) and 10 μMPh-Cipro (n = 143) after 24 h of treatment. All treatment groups had P<0.05
compared to control (Kruskal-Wallis statistical test and Dunn’s Multiple Comparison Test).
doi:10.1371/journal.pone.0125705.g004
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evident in dividing tachyzoites treated with 5 μM Et-Cipro for 24 h (Fig 5F). Apicoplast is lo-
calized posterior to budding daughter cells boundaries (arrow), which implicates the loss of
this organelle after completion of the division process.
Tachyzoites treated with Cipro also shows cell division arrest, apicoplast
missegregation and IMC alteration
Although the effect of Cipro in inhibiting the apicoplast genome replication has been already
shown [8, 31], the phenotype induced by this drug in T. gondii has never been studied. In order
to verify and confirm that the alterations caused by Cipro derivatives are specific, we also evalu-
ated the effect of Cipro (original molecule) by immunofluorescence and TEM. For that, tachy-
zoites were treated with 20 μM of Cipro for 24, 48 and 72h.
While the treatment of tachyzoites with Cipro for 24h has not induced any significant alter-
ation, the treatments for 48h and 72h caused the same phenotype observed for Cipro deriva-
tives (Fig 6). As well as seen for Cipro derivatives, Cipro also caused cell division arrest (Fig
6A–6E). The quantification of the number of parasitophorous vacuoles containing parasites
presenting cell division arrest showed that the treatment with 20 μM of Cipro for 48 and 72 h
affected 24 and 26% of the vacuoles, respectively. ‘Tethered’ daughter cells were observed after
48 and 72 h of treatment with Cipro by immunofluorescence (arrowheads in Fig 6C–6E) and
TEM (Fig 6G). Enlarged parasites in division process (asterisks) and containing additional
IMC profiles in the cytoplasm (inset) were observed by TEM after Cipro treatment for 48 h
(Fig 6F and inset). After 72 h of treatment the presence of multiple well-delimited daughter
cells—the presence of a single individualized nucleus (N) by each daughter is evident—in the
interior of a large parasite after (Fig 6G), points that Cipro also inhibited T. gondii the final
step of cytokinesis. After Cipro treatment for 72 h, vacuoles containing large degenerated
parasites showing abnormal nucleus size were also often observed (Fig 6E arrow) by
immunofluorescence.
Apicoplast missegregation (arrow) and mispositioning (large arrow) events (Fig 6C and
6C’), basal end widening (square brackets in Fig 6C and 6F) and parasites displaying regions of
pellicle without IMC (asterisk in Fig 6D and arrows in Fig 6H) were also observed after treat-
ment with Cipro derivatives. In Fig 6C’ rosette 2, an elongated apicoplast was excluded of one
forming daughter cell (arrow) during endodyogeny and large arrow points to an apicoplast lo-
calized at the posterior end of the parasite. Apicoplast missegregation and mispositioning dur-
ing parasite division might be the cause of apicoplast loss after Cipro treatment.
Cipro derivatives affect MORN1 localization during parasite division
Considering the crucial role of the protein MORN1 in organizing T. gondii basal complex—cy-
toskeletal structure at the basal end of the parasite [32]—and to promote daughter cell scission
Fig 5. Transmission electronmicroscopy analysis of tachyzoites treated with Cipro derivatives. (A) Untreated cells infected with parasites undergoing
normal cell division by endodyogeny. IMC (arrowheads) scaffolds daughter cells while nucleus (N) is undergoing closed mitosis. Each daughter cell is
inheriting one apicoplast (inset). (B) Tachyzoites of T. gondii treated with 1 μMEt-Cipro for 48 h. Treatment led to parasite cell division arrest. Arrowheads
point at daughter cells delimited by the inner membrane complex and show ‘tethered’ daughter parasites. (C) T. gondii tachyzoites treated with 5 μMAdam-
Cipro for 24 h. Treatment led to parasite cell division arrest, leading to the formation of ‘tethered’ daughter cells. This derivative also affected the formation of
the inner-membrane complex (IMC), and one of the daughter cells is devoid of this structure (arrowhead and inset). (D) 5 μMEt-Cipro for 24 h. Treatment
increased the IMC basal gap length and apicoplast positioning. Arrowhead points to the region of the parasite’s surface devoid of an IMC (gap). (E)
Tachyzoites treated with 5 μMEt-Cipro for 48 h. Part of the IMC envelope is missing (arrowhead) in the apical region of a daughter cell budding (arrow points
to IMC scaffolding the daughter cell bud). (F) Tachyzoites treated with 5 μMEt-Cipro for 48 h. Treatment caused apicoplast (inset) to be positioned outside
the boundaries of the daughter cell IMC (arrowhead), which is likely to lead to apicoplast missegregation during parasite division. A-apicoplast; HC-host cell;
M- mitochondrion; N-nucleus; PV-parasitophorous vacuole; Rp-ropthries. Scale bars: (A) 1 μm, 0.2 μm inset; (B) 2 μm (C) 0.5 μm, 0.2 μm inset; (D) 1 μm; (E)
1 μm; (F) 1 μm, 0.2 μm inset.
doi:10.1371/journal.pone.0125705.g005
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in the division process [33–35], we evaluated the distribution of MORN1 after treatment with
Cipro derivatives and Cipro by immunofluorescence using a specific antibody against
this protein.
MORN1 localizes at the basal complex of the parasite (arrow) and also at the final end of
the IMC in budding daughter cells during division (arrowheads) (Fig 7A). A point in the mid-
dle of the cell, corresponding to the centrocone (a cone shape structure in the nuclear envelope
that houses the mitotic spindle [26] was also observed (Fig 7B, curved arrow in rosette 2).
Treatment with 5 μM of Et-Cipro or Adam-Cipro for 24 h and also 20 μM of Cipro for 72h
led to a drastic effect in MORN1 distribution and localization, mainly in dividing parasites (Fig
7B–7F). Tethered daughter cells presenting a wide basal complex (about 2 μm extension), evi-
denced by MORN1 cap, were observed after treatment with 5 μM of Et-Cipro or Adam-Cipro
(Fig 7B and 7D, large arrows). However, tethered daughter cells often presented a weak locali-
zation or lacked MORN1 at the end regions of IMC in mother cell (arrows) and also in budding
daughter cells (arrowheads) after the treatment with 5 μM of Et-Cipro or Adam-Cipro for 24 h
and 20 μM of Cipro for 72 h (Fig 7B, 7C, 7E and 7F). Taking into account the importance of
MORN1 for the assembly of basal complex, and daughter cells scission [35], the lack of this
protein at this region could be associated to the inhibition of daughter cells scission after Cipro
and Cipro derivatives treatment.
Cipro derivatives are less active against the apicomplexan C. parvum
The Apicomplexa species C. parvum lacks an apicoplast [36]. Thus, we hypothesized that if
Cipro derivatives target the apicoplast, these compounds would be less effective at inhibiting C.
parvum proliferation,. To test this hypothesis, the biological activities of Cipro derivatives were
determined by measuring the inhibition of C. parvum growth in MDBK cells (Table 2). Treat-
ments with 50 μM of Ph-Cipro and Adam-Cipro were toxic to host cells (data not shown) and
50 μM of Et-Cipro just inhibited 36% of C. parvum proliferation; despite the toxicity for the
host cells, the treatment with 50 μM of Ph-Cipro and Adam-Cipro did not show to decrease
the proliferation of C. parvum, as infected cells showed a number of parasites similar to the cul-
tures treated with 25 μM (data not shown). Therefore, the IC50 value was only estimated for
Cipro (39.2 μM after 24h; Table 2).
Discussion
Few therapy options are currently available for toxoplasmosis treatment, and effective drugs
have serious toxic effects, leading to treatment interruption. The discovery of the apicoplast in
the phylum Apicomplexa – which includes T. gondii and other important human parasites,
such as Plasmodium spp.—brought new perspectives for the development of chemotherapy
against these parasites, represented by the targeting of the multiple metabolic routes of pro-
karyotic origin found in this organelle, and which differ significantly from those found in
mammalian cells. Inhibitors of apicoplast enzymes, such as azithromycin and clindamycin
Fig 6. Treatment of T. gondiiwith Cipro also leads to cell division arrest, apicoplast missegregation and IMC alteration. Tachyzoites of T. gondii were
treated with 20 μM of Cipro for 24, 48 and 72 h. (A) Quantification of vacuoles (n = 120) containing parasites presenting cell division arrest after treatment with
20 μM of Cipro for 24, 48 and 72 h, results are the mean of two independent experiments. (B-H) Immunofluorescence and TEMmicroscopy of LLC-MK2 cells
infected with tachyzoites of T. gondii and treated for 48 and 72 h with 20 μMCipro. For immunofluorescence parasites were labeled with anti-HSP60
(recognizing the apicoplast, in green), anti-IMC1 (recognizing the inner membrane complex or IMC, in red) antibodies and DAPI (to label the DNA). While
untreated tachyzoites presented normal morphology (B), parasites treated for 48 and 72 h presented cell division arrest, such as ‘tethered’ parasites (C-E
and G), abnormally-shaped basal complexes (C and F square brackets, and inset), missegregated (C’ arrow) and mispositioning apicoplasts (C’ thick
arrows), parasites displaying regions of pellicle without IMC (asterisk in D and arrows in H) and large degenerated parasites showing abnormal nucleus size
(E arrow).
doi:10.1371/journal.pone.0125705.g006
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(which block prokaryotic protein synthesis), are already used in the treatment of human infec-
tions caused by apicomplexan parasites [5, 37]. In a previous study, we showed that derivatives
of the antibiotic ciprofloxacin, a fluoroquinolone inhibitor of prokaryotic type II topoisomer-
ases (DNA gyrase and topoisomerase IV), are active against T. gondii tachyzoites in vitro [20].
Fig 7. Cipro derivatives and Cipro affect MORN1 localization during parasite division. In parasites presenting normal division process MORN1
localizes at the basal complex of the mother cell (arrow) and also caps the final end of the IMC in budding daughter cells (arrowheads) (A), a single strong
point in the middle of the cell was also observed in normal non-dividing parasites (B rosette 2 curved arrow). Tethered daughter cells resulting from the
treatment with 5 μMEt-Cipro (B-C) and Adam-Cipro (D-E) for 24h, and 20 μMCipro for 72h (F) showed wide MORN1 basal caps (B and D large arrows) and
lack or a weak deposition of MORN1, at the basal end of mother (arrow) and budding daughter cells (arrowheads) (B-F)
doi:10.1371/journal.pone.0125705.g007
Table 2. Effect of treatment with Cipro, Et-Cipro, Adam-Cipro and Ph-Cipro on the growth of Cryptosporidium parvum sporozoites in host cells.
Compound % inhibition of sporozoites growtha
12.5 μM 25 μM 50 μM
Cipro 19.5 ± 1.1 46.1 ± 2.9 53.40 ± 2.51
Et-Cipro 20.3 ± 10.1 32.6 ± 7.6 36.43 ± 9.76
Adam-Cipro 24.7 ± 8.4 34.2 ± 3.8 -
Ph-Cipro 33.6 ± 11.6 42.6 ± 14.6 -
a The % sporozoite growth inhibition was calculated by the examination of at least 1000 MDBK cells.
doi:10.1371/journal.pone.0125705.t002
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Here, we show that Cipro derivatives also increase the survival of mice infected with T. gondii,
and affect parasite cell division by inhibiting cytokinesis and disturbing apicoplast duplication
and segregation.
The in vivo studies showed that Cipro derivative administration was well tolerated (Table 1)
and did not result in serious toxicity to mice, and only mild toxicity was observed after treat-
ment with high doses (200mg/kg) of Ph-Cipro (Table 1). While all mice treated with Cipro
died by day 10 post-infection, some mice treated with Cipro derivatives remained alive for at
least 60 days, suggesting that Cipro derivatives cured T. gondii infection in treated mice. Con-
sidering that we used an acute model of infection, the modest rate of mice survival (13–25%)
after treatment with Cipro derivatives is not irrelevant. High mice mortality was also observed
in acute model of infection after the administration of drugs used for the treatment of toxoplas-
mosis in the clinic [38–40]. Thus, Cipro derivatives should be considered potentially promising
for the treatment of toxoplasmosis.
Fichera and Ross (1997) [8] showed that treatment of T. gondii with Cipro led to progressive
loss of apicoplast DNA, without affecting the first round of parasite proliferation in the host
cells. However, egressed parasites that had been treated with Cipro suffered a drastic and per-
manent reduction in the rate of cell duplication in the second round of proliferation in a new
host cell [8]. This ‘delayed effect’ of drugs on parasite proliferation was also seen after treat-
ment of T. gondii and P. falciparum with clindamycin [41, 42].
Interestingly, our results show that esterified Cipro derivatives did not trigger the same de-
layed pattern of parasite death observed after treatment of infected cells with Cipro [8]. Rather,
Et-Cipro and Adam-Cipro inhibited the first cell division event within the first round of para-
site proliferation in host cells (Fig 2), since treatment with these Cipro derivatives for just 6 h
led to a dramatic reduction in the number of parasitophorous vacuoles containing 2 parasites,
7h post-infection (Fig 2A). A possible explanation for these results is that esterified compounds
act as prodrugs and this change would make them more lipophilic, favoring the diffusion
across biological membranes (mainly the multiple membranes of T. gondii and of the apico-
plast) and thus would affect apicoplast in a faster manner than the original molecule (Cipro). It
is noteworthy to mention that Et-Cipro is a mere Cipro precursor, i.e. once inside the cell, Et-
Cipro ethyl ester group is hydrolysed by the action of intracellular esterases and then this deriv-
ative is converted to Cipro (original molecule). Thus, the antiproliferative effect and the mor-
phological alterations caused by Et-Cipro derivative against T. gondii can be credited to Cipro
itself. An immediate effect on the proliferation of T. gondii was also observed after treatment
with the fluoroquinolones gatifloxacin and trovafloxacin [43,44]. So that more active com-
pounds seems to subvert the delayed effect on apicoplast. The IC50 values obtained for gatiflox-
acin (0.52 μM in HFF primary cell culture after 48h) and trovafloxacin (1.37 μM in L929 cell
line) against T. gondii [43,44] were close to those obtained for Cipro derivatives (0.42 μM Et-
Cipro, 0.46 μMAdam-Cipro and 1.24 μM Ph-Cipro after 48h) [20]. The increased activity by
ethyl-esterified Cipro derivatives had also been previously reported in P. falciparum [45]. In-
deed, Cipro had an immediate effect against P. falciparum and did not show the delayed phe-
notype [46]. Therefore, the delayed effect of Cipro against T. gondii is possibly due to its poor
diffusion through T. gondiimembranes.
Although Cipro shows a delayed effect against T. gondii, treatment with this drug induced a
set of alterations identical to those caused by Cipro derivatives treatments (Figs 4–7) and points
that they are acting in the same target. Moreover, the biological activity of Cipro derivatives
against C. parvum, which lacks an apicoplast (Table 2), is, approximately, 50 fold lower than
that in T. gondii tachyzoites [20], reinforcing the notion that treatment with Cipro derivatives
affects the apicoplast directly. The effect of Cipro against this apicomplexa, however, is not
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surprising, as a moderate effect of Cipro against C. parvum has been reported before [47], and
Cipro is possibly acting by an off target in this parasite.
Homologous genes for subunit A of the DNA gyrase—the putative target of the Cipro deriv-
atives used in this study—were identified in the nuclear genome of apicomplexans, and their
protein products are targeted to the apicoplast [18,19]. Thus, it is not surprising that we ob-
served apicoplast alteration after treatment with Cipro derivatives and Cipro (Figs 4B–4D, 5D,
5F and 6C’). Our immunofluorescence and TEM data strongly suggest that the apicoplast loss
observed in some cells after Cipro derivatives and Cipro treatments is likely caused by apico-
plast missegregation during cell division (Figs 4D–4E, 5D, 5F and 6C’). Apicoplast division is
concomitant with mitosis and is closely associated with the centrosome and with the nuclear
spindle poles [48, 49], which is likely to ensure the correct segregation of this organelle to
daughter cells [48]. To date, no protein involved in the physical link between the apicoplast
and the centrosome has been identified.
Immunofluorescence and TEM analyses suggest that, aside from apicoplast duplication and
segregation inhibition, treatment with Cipro derivatives also affected the final step of parasite
cytokinesis (cell scission), which involves constriction at the basal end of dividing parasites and
cell separation. These observations suggest that parasites were able to perform mitosis (Fig 3),
but were unable to complete cell scission at the end of cytokinesis, which occurs just after
daughter cells bud out of the mother cell [27]. Consequently, parasites remained linked togeth-
er at their basal ends, leading to the formation of groups of tethered parasites. This might have
been the main effect of Cipro derivative treatment, since it was also visualized in parasites treat-
ed with a concentration close to the IC50 (1 μM Et-Cipro or Adam-Cipro; Fig 4C and 4F). Cell
scission inhibition was also observed after treatment with 20 μMCipro for 48 and 72h (Fig
6A–6E). Treatment with Cipro also led to impairment of P. falciparum cell division. After
treatment with Cipro, parasites were able to initiate cell division, but failed in forming mature
schizonts [50].
The immediate cell scission inhibition by Cipro derivatives is likely responsible for the
strong parasite proliferation inhibition caused by Et-Cipro and Adam-Cipro treatments, which
led to the formation of ‘tethered’ parasites, where multiple rounds of cell duplication had oc-
curred in the absence of cytokinesis completion. The presence of vacuoles containing multiple
tethered daughter cells even after Cipro derivatives (Et-Cipro and Adam-Cipro) removal (S2
Fig) showed that cell scission inhibition was irreversible, as daughter cells forming from new
division cycles after drug removal were also unable to complete cytokinesis.
Our TEM and immunofluorescence results suggest that Cipro derivatives and Cipro treat-
ments affected the integrity of IMC in mother cell (Fig 6H), as well as, the formation of this
structure in daughter cells during cell division (Figs 5C, 5F, and 6D). The IMC supports the
subpellicular microtubules [29], is important for parasite motility and host cell invasion [51],
and serves as a scaffold for newly assembled structures during daughter cell formation [27, 52].
During daughter cell budding, daughter IMCs is assembled de novo [53], which possibly re-
quires large amounts of lipids. Although T. gondii can obtain fatty acids from the host cell [54],
apicoplast fatty acid synthesis is also essential for parasite survival [11, 55], since the apicoplast
is likely the main source of short-chain fatty acids (C14:0 and C16:0), and cooperates with the
endoplasmic reticulum in the synthesis of long-chain fatty acid [55]. Thus, loss of apicoplast
function by Cipro derivative treatment is expected to affect fatty acid synthesis and
IMC formation.
Other intriguing finding is the lack of MORN1 deposition in the basal end of tethered
daughter cells in parasites presenting cell division inhibition after treatment with Cipro deriva-
tives and Cipro (Fig 7). MORN1 is the major basal complex component and ‘caps’ the posterior
(or basal) end of the parasite [48, 49]. At the very beginning of daughter buds assembling,
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Morn1 forms a pair of rings around early duplicated centrioles [32, 33], and caps and migrates
in synchrony with the IMC during daughter cells budding [33, 56]. Late in cytokinesis, the
basal complex protein components constrict the basal end of newly formed parasites, eventual-
ly ‘resolving’ cell division [32–34, 56]. MORN1 showed an essential role in the assembly and
maturation of basal complex, in its absence other components of the basal complex such as,
Centrin2, dynein light chain and a set of basal IMC proteins could not assemble in the basal
end of the parasite [32–35]. Knockout of MORN1 leads to cytokinesis and apicoplast segrega-
tion defects [34, 35], with the formation of ‘Janus-headed’ parasites [34] and also parasites with
basal end wider than normal [35]. This phenotype is similar to the effect of Cipro derivatives
and Cipro treatments described here (Figs 4B–4G, 5B, 5C and 6A–6G). By immunofluores-
cence microscopy, we observed tethered tachyzoites with a wide basal end after Cipro deriva-
tive treatment (Figs 4B, 4D, 6C and 7B and 7D), and TEM images of parasites treated with
5 μM Et-Cipro and 20 μMCipro show tachyzoites with a wider basal region devoid of an un-
derlying IMC envelope (arrowheads in Fig 5D and square bracket in Fig 6F, respectively).
Thus, the inability of parasites treated with Cipro derivatives and Cipro to perform cell scission
might be due to impaired basal complex maturation due to the lack of MORN1.
Overall, our in vivo and in vitro studies show that Cipro derivatives deserve to be exploited
further in the search for alternative chemotherapeutic agents to treat human toxoplasmosis.
Supporting Information
S1 Fig. Plaque assay showing the antiproliferative effect of Cipro derivatives after 10 days
treatment.While untreated culture (control) shows diverse plaques, treatment with just
0.5 μM of Adam-Cipro or 10 μMCipro led to a drastic reduction on parasite proliferation. In-
deed, no plaques were observed in cultures treated with 5 μM of Adam-Cipro or Et-Cipro,
10 μM of Ph-Cipro and 20 μM of Cipro.
(TIF)
S2 Fig. The effect of Cipro derivatives in T. gondii division is irreversible. Immunoluores-
cence microscopy of tachyzoites labeled with anti-HSP60 (recognizing the apicoplast, in green)
and anti-IMC1 (recognizing the inner membrane complex or IMC, in red) antibodies, and
treated with Cipro derivatives for 6 h and then observed and kept in culture for a further 18h in
the absence of drugs. Parasite division defects were observed (arrows) as a result of Cipro deriv-
ative treatment in the first event of tachyzoite division inside host cells. Even after drug removal
from the medium, cell division continued to be affected. Images represent maximum projec-
tion of optical slices.
(TIF)
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